Investor Relations

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, an investigational sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The proven Durasert drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Recent Releases

Sep 29, 2022
EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 PAVIA Clinical Trial of EYP-1901 for the Treatment of Non-Proliferative Diabetic Retinopathy
Sep 16, 2022
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sep 06, 2022
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Aug 03, 2022
EyePoint Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Developments
Aug 02, 2022
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences

IR CONTACTS
Stern Investor Relations
p. 212.362.1200
e. eyepoint@sternir.com

MEDIA RELATIONS CONTACT
Amy Phillips
p. 412.327.9499
e. aphillips@greenroompr.com